🔎 Trials Near Me

홈 › 비소세포폐암 › 메릴랜드

메릴랜드의 비소세포폐암 임상 시험

비소세포폐암 관련 연구 76개가 메릴랜드 내 여러 지역에서 참여자를 모집하고 있습니다.

메릴랜드의 도시

공식 연구 텍스트(영어)

Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

  • Luminis Health Anne Arundel Medical Center, Annapolis
  • Greater Baltimore Medical Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • 외 7개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT04267848

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

  • Maryland Oncology Hematology (MOH) ( Site 8102), Rockville
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06623422

Tissue Procurement and Natural History Study of People With Non-Small Cell Lung Cancer, Small Cell Lung Cancer, Extrapulmonary Small Cell Cancer, Pulmonary Neuroendocrine Tumors, and Thymic Epithelial Tumors

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT02146170

Trial of Therapeutic Cancer Vaccine OSE2101 in Patients With Non-Small Cell Lung Cancer and Secondary Resistance to Immune Checkpoint Inhibitor

  • Ascension Saint Agnes Hospital, Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT06472245

A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Local Institution - 0123, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 2. 업데이트됨 · NCT07680764

Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors

  • Exelixis Clinical Site #14, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT05176483

A Study of Investigational Agents in Participants With Previously Treated Stage IV Nonsquamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-01H/KEYMAKER-U01)

  • MedStar Franklin Square Medical Center ( Site 0033), Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06780085

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • Johns Hopkins University, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06172478

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

  • UM Upper Chesapeake Hematology and Oncology - Aberdeen, Aberdeen
  • UPMC Western Maryland, Cumberland
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06498635

A Platform Study in Non-Small Cell Lung Cancer (NSCLC)

  • Research Site, Baltimore
피험자 모집 중1/2상
18세 이상 · 모든 성별 · 2026. 10. 1. 업데이트됨 · NCT06996782

Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

  • Johns Hopkins University of Medicine, Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT06881784

DK222 Study at Hopkins

  • Johns Hopkins Hospital, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 29. 업데이트됨 · NCT07140315

A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  • Maryland Oncology Hematology, P.A., Annapolis
  • Maryland Oncology Hematology, P.A., Bethesda
  • Maryland Oncology Hematology, PA, Brandywine
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT07144280

Biospecimen Procurement for Center for Immuno-Oncology Immunotherapy Protocols

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중관찰 연구
18세 ~ 120세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT02682667

A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer

  • Sidney Kimmel Cancer Center - Bayview Campus, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT05498428

Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중2상
18세 ~ 72세 · 모든 성별 · 2026. 9. 28. 업데이트됨 · NCT03412877

Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  • Maryland Oncology Hematology, P.A., Annapolis
  • Maryland Oncology Hematology, P.A., Bethesda
  • Maryland Oncology Hematology, P.A., Brandywine
  • 외 5개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07222566

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Maryland, Baltimore
  • Maryland Oncology Hematology P A, Silver Spring
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06667076

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT07154290

A Global Phase III Study of Rilvegostomig or Pembrolizumab Monotherapy for First-Line Treatment of PD-L1-high Metastatic Non-small Cell Lung Cancer

  • Research Site, Bethesda
  • Research Site, Frederick
  • Research Site, Silver Spring
  • 외 1개
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 25. 업데이트됨 · NCT06868277

Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer

  • University of Maryland, Baltimore
  • Johns Hopkins Bayview Medical Center, Baltimore
  • James M Stockman Cancer Institute, Frederick
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 24. 업데이트됨 · NCT06890598

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

  • Local Institution - 0505, Annapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06561386

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC ≥ 50%) and Without Actionable Genomic Alterations

  • Research Site, Annapolis
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT06357533

Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

  • Research Site, Baltimore
피험자 모집 중2상
18세 ~ 95세 · 모든 성별 · 2026. 9. 23. 업데이트됨 · NCT05061550

Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer

  • Frederick Health Hospital- James M Stockman Cancer Institute, Frederick
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06712316

A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

  • Local Institution - 0702, Annapolis
  • Maryland Oncology Hematology - Columbia, Columbia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06875310

A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중1상
18세 ~ 120세 · 모든 성별 · 2026. 9. 22. 업데이트됨 · NCT06066138

Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLC

  • University of Maryland Greenebaum Cancer Center, Baltimore
  • Sinai Hospital of Baltimore, Baltimore
  • Medstar Franklin Square, Baltimore
  • 외 2개
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 21. 업데이트됨 · NCT06745882

A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

  • Research Site, Bethesda
  • Research Site, Bethesda
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06692738

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

  • Clinical Study Site, Baltimore
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 18. 업데이트됨 · NCT06767514

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

  • Johns Hopkins, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07349537

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

  • United Theranostics, Glen Burnie
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 17. 업데이트됨 · NCT07020117

Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7

  • The Sidney Kimmel Comprehensive Cancer Center, Baltimore
피험자 모집 중2/3상
18세 이상 · 모든 성별 · 2026. 9. 16. 업데이트됨 · NCT04613596

Osimertinib Alone or With Chemotherapy for EGFR-Mutant Lung Cancers

  • John Hopkins Medical Center, Baltimore
피험자 모집 중2상
18세 이상 · 모든 성별 · 2026. 9. 11. 업데이트됨 · NCT04410796

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer

  • Saint Agnes Hospital - Baltimore - Hunt - PPDS, Baltimore
  • Walter Reed National Military Medical Center, Bethesda
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06793215

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

  • Johns Hopkins Bayview Medical Center, Baltimore
  • USO - Maryland Oncology Hematology, Columbia
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 8. 업데이트됨 · NCT06119581

Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations

  • Research Site, Baltimore
  • Research Site, Brandywine
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 9. 4. 업데이트됨 · NCT07291037

Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer

  • University of Maryland Marlene & Stewart Greenebaum Comprehensive Cancer Center, Baltimore
피험자 모집 중1상
18세 이상 · 모든 성별 · 2026. 9. 3. 업데이트됨 · NCT06343402

T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

  • National Institutes of Health Clinical Center, Bethesda
피험자 모집 중2상
18세 ~ 72세 · 모든 성별 · 2026. 8. 31. 업데이트됨 · NCT02133196

Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

  • Research Site, Bethesda
피험자 모집 중3상
18세 이상 · 모든 성별 · 2026. 8. 26. 업데이트됨 · NCT06350097

ClinicalTrials.gov 출처, 2026. 10. 5. 기준 데이터입니다. 각 연구는 자체적인 자격 기준을 설정하며, 연구 팀이 참여자를 결정합니다.